Johnson & Johnson developing stem cell cure for Type 1 diabetes


Johnson & Johnson and biotech company ViaCyte are exploring a possible cure for Type 1 diabetes with encouraging results, The Associated Press reports. The stem cell treatment involves turning embryotic stem cells into insulin-producing cells in a lab, and then putting them in a small capsule to implant under a patient's skin.
Patients with Type 1 diabetes cannot produce insulin. In a healthy person, insulin is made by the body in response to rising blood sugar levels after a meal. High levels of sugar in the bloodstream can lead to the damage of blood vessels, organs, and can even kill patients. Type 1 diabetes patients need to take frequent insulin injections as a result — something the insulin-implant produced by ViaCyte and Johnson & Johnson would render unnecessary.
Testing began on patients a year ago; they received a small dose of the insulin-producing cells in their implants and are to be closely monitored for two years. The companies reported that after 12 weeks, the patient's devices were working as expected with no side effects observed. Another several rounds of patient testing are expected before regulators will approve the device.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
About 29.1 million Americans have diabetes, which includes 1.25 million with Type 1, or insulin-dependent, diabetes. Type 2 diabetics — whose bodies make insulin but use it ineffectively — are on the rise, as are Type 1 diabetics. Current treatment includes a strict diet, exercise, and multiple daily insulin injections and finger-prick blood tests.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Jeva Lange was the executive editor at TheWeek.com. She formerly served as The Week's deputy editor and culture critic. She is also a contributor to Screen Slate, and her writing has appeared in The New York Daily News, The Awl, Vice, and Gothamist, among other publications. Jeva lives in New York City. Follow her on Twitter.
-
How will Trump's megabill affect you?
Today's Big Question Republicans have passed the 'big, beautiful bill' through Congress
-
Scientists are the latest 'refugees'
In the spotlight Brain drain to brain gain
-
5 dreamy books to dive into this July
The Week Recommends A 'politically charged' collection of essays, historical fiction goes sci-fi and more
-
Ukraine scrambles as Trump cuts weapons deliveries
Speed Read The halting of weapons shipments was driven by Pentagon policy chief Elbridge Colby, a Ukraine funding skeptic
-
IAEA: Iran could enrich uranium 'within months'
Speed Read The chief United Nations nuclear inspector, Rafael Grossi, says Iran could be enriching uranium again soon
-
One year after mass protests, why are Kenyans taking to the streets again?
today's big question More than 60 protesters died during demonstrations in 2024
-
Iran nukes program set back months, early intel suggests
Speed Read A Pentagon assessment says US bombing of Iranian nuclear sites only set the program back by months, not years. This contradicts President Donald Trump's claim.
-
Trump says Iran and Israel agreed to ceasefire
Speed Read This followed a night of Israeli airstrikes on Tehran and multiple waves of missiles fired by Iran
-
Israel strikes Iran, killing military and nuclear chiefs
Speed Read Israeli officials said the attack was a 'preemptive' strike on Iran's nuclear program
-
Israel deports Thunberg after seizing Gaza aid boat
speed read The Swedish activist was delivering food and medical aid to Palestine, highlighting the growing humanitarian crisis there
-
Colombian senator shot on streets of Bogotá
speed read Miguel Uribe Turbay, who has announced his candidacy for next year's presidential election, was shot at a rally